Nap B.V. Forgrowth Sells 29,846 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) major shareholder Nap B.V. Forgrowth sold 29,846 shares of the firm's stock in a transaction that occurred on Monday, December 30th. The shares were sold at an average price of $25.54, for a total value of $762,266.84. Following the completion of the sale, the insider now directly owns 10,656,172 shares in the company, valued at approximately $272,158,632.88. The trade was a 0.28 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link. Large shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.

Nap B.V. Forgrowth also recently made the following trade(s):

• On Thursday, December 26th, Nap B.V. Forgrowth sold 33,438 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $26.01, for a total value of $869,722.38.
• On Monday, December 23rd, Nap B.V. Forgrowth sold 25,132 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $25.49, for a total value of $640,614.68.
• On Friday, December 20th, Nap B.V. Forgrowth sold 49,772 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $25.60, for a total value of $1,274,163.20.
• On Wednesday, December 18th, Nap B.V. Forgrowth sold 100,728 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $26.10, for a total value of $2,629,000.80.
• On Thursday, December 12th, Nap B.V. Forgrowth sold 166,011 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $25.39, for a total transaction of $4,215,019.29.
• On Monday, November 18th, Nap B.V. Forgrowth sold 33,273 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $25.08, for a total transaction of $834,486.84.
• On Friday, November 15th, Nap B.V. Forgrowth sold 8,530 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $25.02, for a total transaction of $213,420.60.

NewAmsterdam Pharma Trading Up 1.0 %

Shares of NAMS stock traded up $0.26 during midday trading on Thursday, hitting $25.96. The company had a trading volume of 727,498 shares, compared to its average volume of 379,852. The company's 50 day simple moving average is $22.39 and its 200 day simple moving average is $19.30. NewAmsterdam Pharma has a 52-week low of $11.57 and a 52-week high of $27.29.

Hedge Funds Weigh In On NewAmsterdam Pharma

Large investors have recently bought and sold shares of the company. FMR LLC raised its position in NewAmsterdam Pharma by 35.6% in the third quarter. FMR LLC now owns 330,412 shares of the company's stock worth $5,485,000 after acquiring an additional 86,712 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of NewAmsterdam Pharma by 1,231.0% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 239,283 shares of the company's stock valued at $3,972,000 after purchasing an additional 221,305 shares in the last quarter. abrdn plc lifted its stake in shares of NewAmsterdam Pharma by 69.8% in the third quarter. abrdn plc now owns 129,060 shares of the company's stock valued at $2,142,000 after purchasing an additional 53,060 shares during the period. Millennium Management LLC boosted its holdings in NewAmsterdam Pharma by 23.0% during the second quarter. Millennium Management LLC now owns 1,165,429 shares of the company's stock worth $22,388,000 after buying an additional 217,902 shares in the last quarter. Finally, Jennison Associates LLC grew its position in NewAmsterdam Pharma by 8.9% during the third quarter. Jennison Associates LLC now owns 1,020,278 shares of the company's stock worth $16,937,000 after buying an additional 83,115 shares during the period. Hedge funds and other institutional investors own 89.89% of the company's stock.

Wall Street Analysts Forecast Growth

NAMS has been the topic of several recent research reports. Needham & Company LLC restated a "buy" rating and set a $36.00 target price on shares of NewAmsterdam Pharma in a report on Thursday, December 5th. HC Wainwright started coverage on NewAmsterdam Pharma in a research note on Monday. They set a "buy" rating and a $48.00 price objective on the stock. Scotiabank raised their target price on NewAmsterdam Pharma from $35.00 to $47.00 and gave the stock a "sector outperform" rating in a research note on Wednesday, December 11th. Piper Sandler reiterated an "overweight" rating and set a $37.00 price target on shares of NewAmsterdam Pharma in a report on Monday, September 23rd. Finally, Royal Bank of Canada restated an "outperform" rating and set a $31.00 price target on shares of NewAmsterdam Pharma in a report on Thursday, September 5th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $38.17.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.